Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 2 of 2 entries
View as:
Phase: N/A
Priority: Normal
Start: 06/01/25
End: 06/01/32
Due: 06/01/33
Phase: N/A
Priority: Normal
Start: 06/01/25
End: 06/01/34
Due: 06/01/35
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL | NCT07014917 | Zulfa Omer | user2@example.com | None | 2025-06-01 | 2032-06-01 | 2033-06-01 | - | - | 2025-07-14 |
| LP-168 and Obinutuzumab for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Variants of This | NCT06978088 | Zulfa Omer | user2@example.com | None | 2025-06-01 | 2034-06-01 | 2035-06-01 | - | - | 2025-07-14 |